Fig. 6From: PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysisMeta-regression analysis for the interaction of difference between PCSK9 inhibitors group and control group in LDL-C level change on the risk of new-onset diabetes. LDL-C low-density lipoprotein cholesterol, PCSK9 proprotein convertase subtilisin/kexin 9Back to article page